Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intracoronary multimodal imaging study of intensive lipid-lowering therapy in acute coronary syndrome
ChiCTR2300076092Phase 4Recruiting
- Sponsor
- The Second Hospital of Tianjin Medical University
- Start
- Oct 2023
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial of alirocumab and atorvastatin in acute coronary syndrome (ACS) (2 arms), sponsored by The Second Hospital of Tianjin Medical University. Primary endpoints: all-cause death, cardiogenic death and 2 more. Started Oct 2023; status: recruiting.
02
Drugs
alirocumabatorvastatin
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on ChiCTR2300076092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300076092.